Method of action:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 2020-04-07
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
Human Albumin Biotest 20%, solution for infusion
Lyophilized powder or a porous mass of white or white with a yellowish tinge of color.
After dissolution: translucent homogeneous suspension of white or white with a yellowish tinge of color.
Traumatic and surgical shock, burns accompanied by dehydration, hypoproteinemia and hypoalbuminemia, cirrhosis of the liver, gastrointestinal lesions (peptic ulcer disease, tumors, impaired patency of gastrointestinal anastomosis), acute pancreatitis, brain edema, prolonged suppurative processes, dystrophy, nephropathic syndrome.
In/in, drip, at a rate of 3 ml (50-60 drops) per minute-100-500 ml.
Thrombosis, hypertension, internal bleeding.
Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. In case of shock, standard medical treatment for shock should be implemented.
Albumin should be used with caution in conditions where hypervolaemia and its consequences or haemodilution could represent a special risk for the patient. Examples of such conditions are:
- Decompensated cardiac insufficiency
- Oesophageal varices
- Pulmonary oedema
- Haemorrhagic diathesis
- Severe anaemia
- Renal and post-renal anuria
The colloid-osmotic effect of human albumin 200 g/l is approximately four times that of blood plasma. Therefore, when concentrated albumin is administered, care must be taken to ensure adequate hydration of the patient. Patients should be monitored carefully to guard against circulatory overload and hyperhydration.
200-250 g/l human albumin solutions are relatively low in electrolytes compared to the 40-50 g/l human albumin solutions. When albumin is given, the electrolyte status of the patient should be monitored and appropriate steps taken to restore or maintain the electrolyte balance.
Albumin solutions must not be diluted with water for injections as this may cause haemolysis in recipients.
If comparatively large volumes are to be replaced, controls of coagulation and haematocrit are necessary. Care must be taken to ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets and erythrocytes).
Hypervolaemia may occur if the dosage and rate of infusion are not adjusted to the patient's circulatory situation. At the fist clinical signs of cardiovascular overload (headache, dyspnoea, jugular vein congestion), or increased blood pressure, raised venous pressure and pulmonary oedema, the infusion is to be stopped immediately.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
There are no reports of virus transmissions with albumin manufactured to European Pharmacopoeia specifications by established processes.
It is strongly recommended that every time that Human Albumin Biotest 20% is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
This medicinal product contains 122 mmol sodium per litre. To be taken into consideration by patients on a controlled sodium diet.
No specific interactions of human albumin with other products are known.
There are only limited data on the use of paclitaxel in pregnant women.
It is assumed that when prescribed during pregnancy, paclitaxel causes severe birth defects. In animal studies, the reproductive toxicity of the drug is shown. The use of the drug Abraxan during pregnancy is contraindicated. Women of childbearing age should use reliable methods of contraception.
It is not known whether paclitaxel penetrates into breast milk. Given the possible serious adverse reactions in breastfed children, Abraxane is contraindicated in lactating women. Women who are indicated for treatment with Abraxane should stop breastfeeding.
Fertility. In research in vivo It was found that paclitaxel has genotoxic, teratogenic, embryonic and fetotoxic effects, as well as reduces reproductive function in both males (testicular atrophy/degeneration) and females (a decrease in the number of pregnancy cases and an increase in the number of embryo deaths).
Abraxane causes infertility in male rats. Therefore, men should be advised to consider preserving their own sperm samples before starting treatment, given the risk of developing irreversible infertility during treatment with Abraxane.
No effects on ability to drive and use machines have been observed.
The most frequent and clinically significant adverse drug reactions (NLR) that develop against the background of the use of the drug Abraxan were neutropenia, peripheral neuropathy, arthralgia/myalgia and gastrointestinal disorders. The following are the NLRs registered during treatment with Abraxane - as monotherapy and in combination with gemcitabine — for all possible indications.
The following terms are used in this description to assess the incidence of NLR of the drug: very often (≥1/10), often (<1/10–≥1/100), infrequently (<1/100–≥1/1000), rarely (<1/1000–≥1/10000), very rarely (<1/10000).
Breast cancer (monotherapy with Abraxane)
Infectious and parasitic diseases: common-infections, urinary tract infections, folliculitis, upper respiratory tract infections, candidiasis, sinusitis, infrequently-oral candidiasis, nasopharyngitis, phlegmon, herpes simplex, viral infections, pneumonia, catheter-associated infections, fungal infections, shingles infectious complications at the injection site, sepsis2, neutropenic sepsis2.
Benign, malignant, and unspecified neoplasms (including cysts and polyps): rarely, metastatic pain, necrosis of the tumor.
From the blood and lymphatic system: very often — neutropenia, anemia, leukopenia, thrombocytopenia, lymphopenia, suppression of bone marrow hematopoiesis, often-febrile neutropenia, rarely-pancytopenia.
On the part of the immune system: infrequently1 - hypersensitivity reactions, rarely-severe hypersensitivity reactions.
From the side of metabolism and nutrition: very often-anorexia, often-dehydration, decreased appetite, hypokalemia, infrequently-hypophosphatemia, fluid retention, hypoalbuminemia, polydipsia, hyperglycemia, hypokalemia, hypocalcemia, hypoglycemia, hyponatremia.
Mental disorders: often-insomnia, depression, anxiety, infrequently-anxiety.
From the nervous system: very often-peripheral neuropathy, neuropathy, hypesthesia, paresthesia, often-peripheral sensory neuropathy, headache, dysgeusia, dizziness, peripheral motor neuropathy, ataxia, sensory disorders, increased drowsiness, infrequently-polyneuropathy, decreased reflexes/areflexia, dyskinesia, neuralgia, loss of sensitivity, fainting, postural dizziness, neurogenic pain, tremor.
On the part of the visual organ: often-increased lacrimation, blurred vision, dry eye syndrome, dry keratoconjunctivitis, madarosis, infrequently-eye irritation, eye pain, visual impairment, decreased visual acuity, conjunctivitis, visual perception disorders, itching in the eyes, keratitis, rarely - cystic macular edema2.
On the part of the organ of hearing and labyrinth disorders: often, vertigo, rarely — pain in the ears, tinnitus.
From the heart: often-tachycardia, arrhythmia, supraventricular tachycardia, rarely-bradycardia, cardiac arrest, left ventricular dysfunction, congestive heart failure, AV block2.
From the side of the vessels: often-hot flushes, increased blood pressure, lymphatic edema, infrequently decreased blood pressure, cold extremities, orthostatic hypotension, very rarely — thrombosis.
From the respiratory system, chest and mediastinal organs: often-interstitial pneumonitis3, shortness of breath, nasal bleeding, pharyngolaryngeal pain, cough, rhinitis, rhinorrhea, infrequently — cough with sputum, shortness of breath during exercise, swelling of the sinus mucosa, weakened breathing, pleural effusion, allergic rhinitis, hoarseness, dry/stuffy nose, wheezing, thromboembolism/embolism of the pulmonary artery.
From the gastrointestinal tract: very often — nausea, diarrhea, vomiting, constipation, stomatitis, often — abdominal pain, bloating, epigastric pain, dyspepsia, gastroesophageal reflux, hypesthesia of the oral mucosa, infrequently — dysphagia, flatulence, glossalgia, dry mouth, gum pain, loose stools, esophagitis, lower abdominal pain, ulcerative lesions of the oral mucosa, mouth pain, rectal bleeding.
From the liver and biliary tract: infrequently — hepatomegaly.
From the skin and subcutaneous tissues:2, toxic epidermal necrolysis3.
Musculoskeletal and connective tissue disorders: very often — arthralgia, myalgia, often-pain in the extremities, bone pain, back pain, muscle cramps, pain in the distal extremities, infrequently-chest pain, muscle weakness, neck pain, groin pain, muscle spasms, musculoskeletal pain, side pain, feeling of discomfort in the extremities.
From the kidneys and urinary tract: rarely — dysuria, pollakiuria, hematuria, nocturia, polyuria, urinary incontinence.
From the genitals and breast: infrequently-pain in the mammary gland.
General disorders and disorders at the injection site: very often-fatigue, asthenia, fever, often-peripheral edema, inflammation of the mucous membrane, pain, chills, swelling, weakness, decreased performance, chest pain, flu-like syndrome, malaise, drowsiness, hyperthermia, infrequently-a feeling of discomfort in the chest, gait disorders, swelling, reactions at the injection site, rarely-extravasation.
Laboratory and instrumental data: often-weight loss, increased activity of ALT, ACT, ALP, GTT, decreased red blood cell count, decreased hematocrit, increased body temperature, infrequently-increased blood pressure, increased body weight, hyperbilirubinemia, increased serum creatinine concentration, hyperphosphatemia, hyperglycemia, hyponatremia, increased LDH activity.
Injuries, intoxication, and complications of manipulation: infrequently-bruises, rarely-anamnestic radiation phenomenon, radiation pneumonitis3
1 The frequency of hypersensitivity reactions was determined on the basis of one definitely associated with the drug Abraxane case in a population of 789 patients.
2 According to the post-registration report on the drug Abraxane.
3 The frequency of pneumonitis was calculated based on the generalized data of 1310 patients who participated in clinical trials of the drug Abraxane, which was prescribed as monotherapy for breast cancer and other indications (see "Special instructions").
Pancreatic adenocarcinoma (drug Abraxane in combination with gemcitabine)
Infectious and parasitic diseases: often-sepsis, pneumonia, candidiasis of the oral cavity.
From the blood and lymphatic system: very often-neutropenia, anemia, thrombocytopenia, often-pancytopenia, infrequently-thrombotic thrombocytopenic purpura.
From the side of metabolism and nutrition: very often — dehydration, decreased appetite, hypokalemia.
Mental disorders: very often — insomnia, depression, infrequently-anxiety.
From the nervous system: very often — peripheral neuropathy, dysgeusia, headache, dizziness, infrequently-facial nerve paralysis.
On the part of the visual organ: often-increased lacrimation, infrequently - cystic edema of the macula.
From the heart: often-congestive heart failure, tachycardia.
From the side of the vessels: often-a decrease and increase in blood pressure.
From the respiratory system, chest and mediastinal organs: very often-shortness of breath, nosebleeds, cough, often-pneumonitis, nasal congestion, infrequently - dry throat/nose.
From the gastrointestinal tract: very often-nausea, diarrhea, vomiting, constipation, abdominal pain, pain in the epigastric region, often — stomatitis, intestinal obstruction, colitis, dryness of the oral mucosa.
From the liver and biliary tract: often-cholangitis.
From the skin and subcutaneous tissues: very often-alopecia, skin rash, often-itching, dry skin, nail diseases, hot flashes.
Musculoskeletal and connective tissue disorders: very often-pain in the extremities, arthralgia, myalgia, often-muscle weakness, pain in the bones.
From the kidneys and urinary tract: often-acute renal failure, infrequently-hemolytic-uremic syndrome.
General disorders and disorders at the injection site: very often — fatigue, peripheral edema, fever, asthenia, chills, often-reactions at the injection site.
Laboratory and instrumental data: very often-weight loss, increased ALT activity, often-increased ACT activity, hyperbilirubinemia, increased creatinine concentration in blood plasma.
Description of individual adverse reactions
From the blood and lymphatic system: Table 4 provides information on the frequency and severity of changes in the indicators of hematological tests in patients receiving the drug Abraxan in combination with gemcitabine or gemcitabine alone.
Pathological changes in the parameters of hematological tests in patients with pancreatic adenocarcinoma
|Hematological parameters||Drug Abraxane (125 mg / m2) /gemcitabine||Gemcitabine|
|1st-4th degree, %||3rd-4th degree, %||1st-4th degree, %||3rd-4th degree, %|
1 The data of 405 patients treated with the combination of Abraxane/gemcitabine were evaluated.
2 The data of 388 patients treated with gemcitabine were evaluated.
3 The data of 404 patients treated with the combination of Abraxane/gemcitabine were evaluated.
Post-marketing experience with the use
During the post-registration study of the drug Abraxan, cases of cranial nerve paralysis, paresis of the vocal cords, and rare cases of severe hypersensitivity reactions were described.
Rare cases of decreased visual acuity due to cystic retinal macular edema have also been reported during therapy with Abraxan. It is necessary to cancel Abraxan when making a diagnosis of cystic edema of the retinal macula. In some patients who received pre-capecitabine, cases of palmar-plantar erythrodysesthesia were noted. Due to the fact that such complications were reported spontaneously during clinical use of the drug, their true frequency and causal relationship cannot be determined.
The specific antidote of paclitaxel is unknown. In the case of an overdose of the drug Abraxane, symptomatic treatment and careful monitoring of the patient are carried out. Treatment should be directed to the main predicted complications (myelosuppression, mucositis, and peripheral neuropathy).
Mechanism of action
The mechanism of action of paclitaxel is based on its ability to stimulate the assembly of mitotic spindle microtubules from dimeric tubulin molecules and to stabilize the microtubules by suppressing their depolymerization. This leads to the suppression of the normal dynamic reorganization of the microtubular network in the mitotic interphase, and also causes the formation of abnormal clusters of microtubules throughout the cell cycle and the appearance of multiple star-shaped clusters (asteroids) in the mitotic phase.
Abraxane contains nanodisperse paclitaxel, stabilized by albumin, with a nanoparticle size of approximately 130 nm, in which paclitaxel is in a non-crystalline (amorphous) state.
After intravenous administration, the nanoparticles rapidly dissociate to form soluble complexes of paclitaxel bound to albumin, with an approximate size of 10 nm. It is known that albumin regulates the processes of transendothelial transfer of plasma components, and in studies in vitro It has been demonstrated that the presence of albumin in the drug Abraxane stimulates the transport of paclitaxel through the endothelial cell layer. It was hypothesized that transendothelial transport is mediated by the gp-60 albumin transporter and there is an increase in the accumulation of paclitaxel in the tumor due to the presence of albumin-binding protein-an acidic secreted protein rich in cysteine (SPARC).
The pharmacokinetics (FC) of paclitaxel was studied in clinical studies with 30-and 180-minute infusions of the drug Abraxane at doses from 80 to 375 mg / m2. The AUC values for paclitaxel increased linearly, from 2653 to 16736 ng * h / ml in the dose range from 80 to 300 mg / m2.
In a study involving patients with advanced solid tumors, the parameters (FC) of paclitaxel after intravenous administration of the drug Abraxan at a dose of 260 mg / m2 for 30 minutes, the parameters of FC were compared with those of the solvent-based paclitaxel at a dose of 175 mg/m.2 for 3 hours. Based on the results of the analysis without taking into account compartments, the clearance of paclitaxel (43%) and Vd its (53%) was higher with the administration of the drug Abraxane than with the solvent-based paclitaxel.
Differences of the terminal T1/2 it was not registered. During the study of multiple intravenous administration of the drug Abraxane at a dose of 260 mg / m2 In 12 patients, the intra-individual variability of the values of the systemic exposure of paclitaxel (AUC) was 19% (the spread of values = 3.21–27.7%). There were no signs of accumulation of paclitaxel during several courses of therapy.
Distribution. After administration of the drug Abraxan to patients with solid tumors, paclitaxel was evenly distributed in blood cells and plasma and bound to plasma proteins by 94% . The binding of paclitaxel to proteins was evaluated by ultrafiltration in a comparison study in the same patient. The proportion of free paclitaxel was significantly higher with the use of Abraxane (6.2%) than with the introduction of solvent-based paclitaxel (2.3%). This provided significantly higher exposure values for the unbound paclitaxel fraction when administered with Abraxane than for solvent-based paclitaxel, even with comparable total exposure values.
This phenomenon is probably due to the lack of binding of paclitaxel to micelles Cremophor EL what is observed when using solvent-based paclitaxel. According to published studies in which in vitro The association of paclitaxel (in concentrations from 0.1 to 50 mcg/ml) with human plasma proteins was evaluated; the presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect the association of paclitaxel with plasma proteins.
Taking into account the results of the population analysis of FC data, the overall Vd is approximately 1741 l, large Vd indicates intensive extravascular distribution and / or binding of paclitaxel to tissue proteins.
Metabolism and excretion. In research in vitro Using liver microsomes and human tissue sections, it was shown that paclitaxel is metabolized primarily to form 6α-hydroxypaclitaxel, as well as two additional metabolites present in smaller amounts (3'-n-hydroxypaclitaxel and 6α-3'-n-dihydroxypaclitaxel). The formation of these hydroxylated metabolites is catalyzed by the cytochrome P450 isoenzymes CYP2C8, CYP3A4, and both CYP2C8 and CYP3A4, respectively.
In patients with metastatic breast cancer after intravenous drip administration of the drug Abraxan for 30 minutes at a dose of 260 mg / m2 the average cumulative urinary excretion of the unchanged active substance corresponded to 4% of the total administered dose of the drug, less than 1% of the administered dose was accounted for by the urinary metabolites 6α-hydroxypaclitaxel and 3'-n-hydroxypaclitaxel, which indicates a significant extrarenal clearance of the drug. Paclitaxel is mainly eliminated by hepatic metabolism and excretion with bile. When the drug is administered at a therapeutic dose of 80 to 300 mg / m2 the average plasma clearance of paclitaxel varies from 13 to 30 l / h / m2, and the middle terminal T1/2 it ranges from 13 to 27 hours.
Special patient groups
Impaired liver function. The results of the conducted clinical studies demonstrated that mild hepatic insufficiency (total bilirubin >1 to < 1.5×ULN) did not have a clinically significant effect on the parameters of paclitaxel FC. In patients with moderate hepatic insufficiency (total bilirubin >1.5 to ≤3×ULN) and severe (total bilirubin >3 to ≤5×ULN), there was a decrease in the maximum elimination rate of paclitaxel by 22-26% and an increase in the average AUC of paclitaxel by about 20%.
Hepatic insufficiency did not affect the mean value of Cmax paclitaxel. In addition, the elimination of paclitaxel was inversely correlated with the total bilirubin and directly proportional to the albumin concentration in the blood plasma.
Pharmacokinetic / pharmacodynamic modeling showed no correlation between liver function (based on baseline albumin or total bilirubin concentrations) and neutropenia, taking into account exposure to Abraxane. FC analysis was not performed in patients with total bilirubin >5×HCV or in patients with metastatic pancreatic adenocarcinoma (see "Dosage and administration").
Impaired renal function. Mild or moderate renal insufficiency (creatinine Cl from ≥30 to <90 ml / min) did not have a clinically significant effect on the maximum elimination rate and systemic exposure (AUC and Cmax) of paclitaxel. There are insufficient FC analysis data for patients with severe renal insufficiency, and there are no data for patients with end-stage renal insufficiency.
Elderly patients. The population FC analysis of the drug Abraxan included data from patients aged 24 to 85 years. The results showed that age does not significantly affect the maximum elimination rate and systemic exposure (AUC and Cmax) of paclitaxel.
Pharmacokinetic / pharmacodynamic modeling using data from 125 patients with advanced solid tumors showed that patients >65 years of age may be more likely to develop neutropenia during the first cycle of therapy, although age did not affect the plasma exposure of paclitaxel.
Other internal factors. Population FC analysis of the drug Abraxan demonstrated that gender, race (Mongoloid versus Caucasian), and type of solid tumors do not have a clinically significant effect on systemic exposure (AUC and Cmax) of paclitaxel. The AUC of paclitaxel in patients with a body weight of 50 kg is approximately 25% lower than in patients with a body weight of 75 kg. The clinical significance of these findings is unknown.
- Enteral and parenteral nutrition products
- Substitutes for plasma and other blood components
Human albumin is a normal constituent of the human plasma and acts like the physiological albumin.
In animals, singledose toxicity testing is of little relevance and does not permit the evaluation of toxic or lethal doses or of a dose-effect relationship. Repeateddose toxicity testing is impracticable due to the development of antibodies to heterologous protein in animal models.
To date, human albumin has not been reported to be associated with embryo-fetal toxicity, oncogenic or mutagenic potential.
No signs of acute toxicity have been described in animal models.
Sodium caprylate (16 mmol/l), Sodium chloride (63 mmol/l), N-acetyltryptophanate (16 mmol/l), water for injections.
Special studies of the interaction of paclitaxel with other drugs have not been conducted. Due to the fact that the metabolism of paclitaxel is partially mediated by the isoenzymes CYP2C8 and CYP3A4 of the cytochrome P450 system, the drug Abraxane should be used with caution together with inhibitors of these isoenzymes (including ketoconazole and other antifungal agents — imidazole derivatives, erythromycin, cimetidine, fluoxetine, gemfibrozil, ritonavir, saquinavir, indinavir and nelfinavir) or inducers of these isoenzymes (including rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine).
Paclitaxel and gemcitabine have different metabolic pathways. The clearance of paclitaxel is mainly due to metabolism catalyzed by the isoenzymes CYP2C8 and CYP3A4, followed by bile excretion, gemcitabine is inactivated by cytidine deaminase, followed by urinary excretion. Studies of the pharmacokinetic interaction of the drug Abraxane and gemcitabine in humans have not been conducted.
The drug Abraxane is indicated as a monotherapy for breast cancer or in combination with gemcitabine for the treatment of pancreatic adenocarcinoma (see "Indications"). The drug Abraxane should not be combined with other antitumor agents.
At a temperature of 2-10 °C.
Keep out of reach of children.Shelf life of the drug Albumin5 лет.
Do not use after the expiration date indicated on the package.Instructions for medical use Альбумин - инструкция по медицинскому применению - РУ № ЛП-000332 от 2016-07-19
Альбумин - инструкция по медицинскому применению - РУ № ЛСР-005894/08 от 2018-08-27
Альбумин - инструкция по медицинскому применению - РУ № ЛС-002362 от 2012-10-08
Альбумин - инструкция по медицинскому применению - РУ № Р N003077/01 от 2008-12-03
Альбумин - инструкция по медицинскому применению - РУ № ЛС-001269 от 2015-06-08
Альбумин - инструкция по медицинскому применению - РУ № ЛСР-003721/07 от 2018-06-28
Альбумин - инструкция по медицинскому применению - РУ № Р N003840/01 от 2009-12-15
Альбумин - инструкция по медицинскому применению - РУ № ЛП-000482 от 2015-12-01
Альбумин - инструкция по медицинскому применению - РУ № ЛС-002362 от 2009-10-22
Альбумин - инструкция по медицинскому применению - РУ № Р N002860/01 от 2013-05-15
Альбумин - инструкция по медицинскому применению - РУ № ЛС-001269 от 2011-10-06
Альбумин - инструкция по медицинскому применению - РУ № ЛСР-001951/09 от 2016-07-19
Альбумин - инструкция по медицинскому применению - РУ № Р N003367/01 от 2004-05-25
Альбумин - инструкция по медицинскому применению - РУ № ЛС-002333 от 2016-08-30
Альбумин - инструкция по медицинскому применению - РУ № Р N002780/01 от 2008-08-15
Альбумин - инструкция по медицинскому применению - РУ № ЛС-000118 от 2018-04-04
Альбумин - инструкция по медицинскому применению - РУ № ЛСР-000790/08 от 2008-02-15
Альбумин - инструкция по медицинскому применению - РУ № Р N003367/01 от 2009-09-17
Альбумин - инструкция по медицинскому применению - РУ № ЛС-002333 от 2012-01-19
Альбумин - инструкция по медицинскому применению - РУ № ЛСР-005651/09 от 2018-04-03
Альбумин - инструкция по медицинскому применению - РУ № ЛП-002141 от 2013-07-12
10% solution for infusions in 100 ml vials.
The solution can be directly administered by the intravenous route, or it can be diluted in an isotonic solution (e.g. 0.9% sodium chloride).
Albumin solutions must not be diluted with water for injections as this may cause haemolysis in recipients.
If large volumes are administered, the product should be warmed to room or body temperature before use.
The solution should be clear or slightly opalescent. Do not use solutions which are cloudy or have deposits. This may indicate that the protein is unstable or that the solution has become contaminated.
Once the container has been opened, the contents should be used immediately. Any unused product should be disposed of in accordance with local requirements.
Biotest Pharma GmbH
Date of first authorisation: 24 Febuary 2009
Date of latest renewal: 21.June 2012
- K25 Stomach ulcer
- K26 Duodenal ulcer
- R57 Shock, not classified elsewhere
- T30 Thermal and chemical burns of unspecified localization
- T79. 4 Traumatic shock
- T81. 1 Shock during or after the procedure, not classified elsewhere